An investment of £138 million ($167 million) from the UK government will help boost vaccines manufacturing capacity, as well as establish a “virtual VMIC” in the country.
The investment is being made in the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization providing strategic vaccine development and advanced manufacturing capability.
The group, which is based at the Harwell campus, just outside Oxford, will receive £93 million to rapidly expand the facility's capabilities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze